Papers from every journal, all in one place. कस्टम फ़ीड बनाएं.
Clinicians should integrate extracranial bleeding risk into OAC decisions for AF; this meta-analysis extends trial data by quantifying baseline factors' contribution to most attributable risk.
BP lowering shows no outcome benefit in HFmrEF/HFpEF; leaves open whether it mediates therapy effects or warrants targeted trials.

Hypertrabeculation in DCM was not linked to higher embolic risk; leaves open its prognostic value across genotypes in prospective studies.

Cardiologist, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC)
The presence of hypertrabeculation did not modify clinical risk in any of the genetic subgroups analyzed, confirming that it does not confer a worse prognosis.
May guide cardioprotective drug selection during breast cancer chemotherapy; extends comparative RCT evidence on LVEF preservation.

Low BP control persisted after 2017 guideline and during COVID; leaves open how to overcome therapeutic inertia in incident hypertension.

May support interpretable ECG analysis for PVC localization; leaves open prospective validation before clinical use.

Diagnostic delays may occur in young adults with high BP, especially men; leaves open whether targeted screening improves timely diagnosis.

EV ICD shows acceptable safety in Japanese patients; extends global data but leaves open need for randomized confirmation.

Enables safe avoidance of admission for troponin-negative chest pain; supports broader adoption of ambulatory CTCA pathways.
Lower SBP (<120 mmHg) and LDL-C (<70 mg/dL) targets may improve kidney outcomes in advanced CKD; leaves open need for RCTs to confirm.